Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 1.00 |
| ▸ | TAAR5 | O14804 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.50 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HTR3A | P46098 | 1/20 | 0.50 |
| ▸ | BACE1 | P56817 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | APEX1 | P27695 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29374539 | 1.00 | TAAR1 (1.00) | TAAR1TAAR5KDM4EALDH1A1HTR1A | |
| SCHEMBL13886676 | 0.88 | TAAR5 (0.79) | TAAR1TAAR5KMT2AMEN1BLM | |
| SCHEMBL13886597 | 0.85 | TAAR1 (0.74) | TAAR1TAAR5KDM4EALDH1A1HTR1A | |
| SCHEMBL13886593 | 0.85 | TAAR1 (0.74) | TAAR1TAAR5CYP1A2CYP3A4TSHR | |
| SCHEMBL25772997 | 0.85 | TAAR1 (0.74) | TAAR1TAAR5KDM4ECYP1A2CYP3A4 | |
| SCHEMBL13886618 | 0.84 | TAAR5 (0.73) | TAAR1TAAR5KDM4ECYP1A2CYP3A4 | |
| Hydrochloric Acid SCHEMBL5311045 | 0.84 | TAAR1 (0.72) | TAAR1TAAR5KMT2AAPEX1MEN1 | |
| Hydrochloric Acid SCHEMBL5317226 | 0.83 | TAAR5 (0.71) | TAAR1TAAR5CYP1A2CYP3A4TSHR | |
| SCHEMBL13886678 | 0.82 | TAAR1 (0.69) | TAAR1TAAR5KDM4EALDH1A1HTR1A | |
| SCHEMBL13886598 | 0.81 | TAAR5 (0.68) | TAAR1TAAR5MAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 350 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11974970-B2 | Muscular atrophy-inducing agent using hypometabolism-inducing substance T1AM, and use thereof in treating muscular hypertrophy | UNIVERSITY INDUSTRY FOUNDATION, YONSEI UNIVERSITY WONJU CAMPUS (KR) | 2024-05-07 | — | — | US | claimed |
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2024-03-28 | — | — | US | claimed |
| CN-117554536-B | Simultaneous analysis method for 15 thyroid hormones in environmental water sample | 北京林业大学 | 2024-03-19 | — | — | CN | claimed |
| CN-117554536-A | Simultaneous analysis method for 15 thyroid hormones in environmental water sample | 北京林业大学 | 2024-02-13 | — | — | CN | claimed |
| US-11441162-B2 | Human gut microbiome-derived biosynthetic enzymes for production of fatty acid amides | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-09-13 | — | — | US | claimed |
| US-20220265775-A1 | COMPOSITIONS AND METHODS FOR TREATING PULMONARY EDEMA OR LUNG INFLAMMATION | UNIV MINNESOTA (US) | 2022-08-25 | — | — | US | claimed |
| EP-3955954-A1 | COMBINATION THERAPY FOR MODULATING BILE ACID HOMEOSTASIS AND TREATMENT OF BILE ACID DISORDERS AND DISEASES | NGM Biopharmaceuticals, Inc. (US) | 2022-02-23 | — | — | EP | claimed |
| US-20210401728-A1 | Topical Compositions and Methods to Promote Optimal Dermal White Adipose Tissue Composition in Vivo | GALANIN IVAN (US) | 2021-12-30 | — | — | US | claimed |
| EP-3876747-A1 | METHODS OF MODULATING GASTROINTESTINAL METABOLITES | DSM IP Assets B.V. (NL) | 2021-09-15 | — | — | EP | claimed |
| US-20210137854-A1 | TAAR Receptor Agonists for the Treatment of Alopecia | JUPITER WELLNESS INC. | 2021-05-13 | — | — | US | claimed |
| US-20180140562-A1 | MUSCULAR ATROPHY-INDUCING AGENT USING HYPOMETABOLISM-INDUCING SUBSTANCE T1AM, AND USE THEREOF IN TREATING MUSCULAR HYPERTROPHY | UNIVERSITY INDUSTRY FOUNDATION, YONSEI UNIVERSITY WONJU CAMPUS (KR) | 2018-05-24 | — | — | US | claimed |
| EP-3289864-A1 | COMPOSITION FOR INDUCING HYPOMETABOLISM, METHOD FOR INDUCING HYPOMETABOLISM, AND FISH TRANSPORTATION METHOD USING TECHNIQUES THEREOF | University Industry Foundation, Yonsei University Wonju Campus (KR) | 2018-03-07 | — | — | EP | claimed |
| US-9328331-B2 | Compositions and methods for promoting beta cell maturity | JOSLIN DIABETES CENTER, INC. (US) | 2016-05-03 | — | — | US | claimed |
| US-9012835-B2 | Methods for simultaneous quantification of thyroid hormones and metabolites thereof by mass spectrometry | GEORGETOWN UNIVERSITY (US) | 2015-04-21 | — | — | US | claimed |
| US-20150099741-A1 | DIAGNOSING AND TREATING PATIENTS HAVING PSYCHIATRIC DISORDERS | NORTHWESTERN UNIVERSITY (US) | 2015-04-09 | — | — | US | claimed |
| US-20140361156-A1 | Methods for Simultaneous Quantification of Thyroid Hormones and Metabolites Thereof by Mass Spectrometry | GEORGETOWN UNIVERSITY (US) | 2014-12-11 | — | — | US | claimed |
| WO-2012087438-A1 | METHODS FOR SIMULTANEOUS QUANTIFICATION OF THYROID HORMONES AND METABOLITES THEREOF BY MASS SPECTROMETRY | GEORGETOWN UNIVERSITY (US) | 2012-06-28 | — | — | WO | claimed |
| US-20120141436-A1 | COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY | JOSLIN DIABETES CENTER, INC. (US) | 2012-06-07 | — | — | US | claimed |
| WO-2010135639-A2 | COMPOSITIONS AND METHODS FOR PROMOTING BETA CELL MATURITY | JOSLIN DIABETES CENTER, INC. (US) | 2010-11-25 | — | — | WO | claimed |
| WO-2007059039-A1 | THYROXINE DERIVATIVES FOR PRECONDITIONING AGAINST STROKE | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2007-05-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101963-A1 | SC-BETA CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME | IAPP, ALPG, PNLIP | TAAR1 4310/4885TAAR5 4411/4885KDM4E 4115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.